{"doi":"10.1016/j.rpth.2024.102334","title":"Procedural outcomes in children with mild type 1 von Willebrand disease","abstract":"Background: In patients with mild type 1 von Willebrand disease (VWD), treatment guidelines suggest individualization of surgical management. However, these conditional recommendations are based on very low-certainty evidence due to limited data on surgical outcomes in this population. Objectives: To characterize procedural bleeding prophylaxis strategies and outcomes in children with mild type 1 VWD. Methods: This is a retrospective cohort study that included patients aged between 0 and 21 years with mild type 1 VWD (defined as von Willebrand factor antigen and/or an activity of 30-50 IU/dL) who underwent a procedure from July 1, 2017, to July 1, 2022. Demographic, surgical, medication, and bleeding data were collected by manual chart review. Results: = 128, 79.5%); desmopressin was used in 17 (10.6%) procedures, and von Willebrand factor concentrate was used in 12 (7.5%) procedures. Bleeding complications occurred in 8 (5.0%) procedures: these included 1 major, 4 clinically relevant nonmajor, and 3 minor bleeding events. No patient required blood transfusion or an additional procedure to achieve hemostasis. Most bleeding complications were seen following intrauterine device (IUD) placement (5/8). Nearly 30% of patients who underwent IUD placement reported bleeding. Conclusion: Pediatric patients with mild type 1 VWD can safely undergo procedures using a tailored approach. Bleeding complications were uncommon, with the majority following IUD placement.","journal":"Research and Practice in Thrombosis and Haemostasis","year":2024,"id":448272,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":5,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9346,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2024-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1266879,"name":"Karen L. Zimowski","orcid":"0000-0003-3819-7200","position":1,"is_corresponding":false},{"id":1154274,"name":"Sadie F. Mason","orcid":"0000-0002-4241-5058","position":2,"is_corresponding":false},{"id":672195,"name":"Michael H. White","orcid":"0000-0002-8638-8741","position":3,"is_corresponding":false},{"id":1267285,"name":"Stefanie DiGiandomenico","orcid":null,"position":4,"is_corresponding":false},{"id":637081,"name":"Caroline Trotter","orcid":"0000-0003-4000-2708","position":5,"is_corresponding":false},{"id":672801,"name":"Robert F. Sidonio","orcid":"0000-0002-9509-9415","position":6,"is_corresponding":false},{"id":672800,"name":"Megan Brown","orcid":"0000-0001-8117-1239","position":7,"is_corresponding":false},{"id":1267284,"name":"Samuel Heery","orcid":null,"position":0,"is_corresponding":true}],"reference_count":21,"raw_metadata":null,"created_at":"2026-07-19T02:02:08.018689Z","pmid":"38440264","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}